Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Prognostic factors for survival in patients with advanced cholangiocarcinoma treated with percutaneous transhepatic drainage

T. Rohan, B. Cechova, P. Matkulcik, M. Straka, J. Zavadil, M. Eid, M. Uher, M. Dostal, T. Andrasina

. 2025 ; 15 (1) : 2172. [pub] 20250116

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc25010249

Grant support
NU21-08-00561 Ministerstvo Zdravotnictví Ceské Republiky
NU21-08-00561 Ministerstvo Zdravotnictví Ceské Republiky
NU21-08-00561 Ministerstvo Zdravotnictví Ceské Republiky
NU21-08-00561 Ministerstvo Zdravotnictví Ceské Republiky
MUNI/A/1611/2023 Ministerstvo Školství, Mládeže a Tělovýchovy
MUNI/A/1611/2023 Ministerstvo Školství, Mládeže a Tělovýchovy
MUNI/A/1611/2023 Ministerstvo Školství, Mládeže a Tělovýchovy
MUNI/A/1558/2023 Ministerstvo Školství, Mládeže a Tělovýchovy
MUNI/A/1611/2023 Ministerstvo Školství, Mládeže a Tělovýchovy
MUNI/A/1611/2023 Ministerstvo Školství, Mládeže a Tělovýchovy

Biliary drainage is then one of the necessary procedures to help patients suffering from icterus to reduce serum bilirubin levels and relieve symptoms. The aim of this study was identifying risk factors for survival in patients with cholangiocarcinoma (CCA) treated with percutaneous transhepatic biliary drainage (PTBD) and to develop a simple scoring system predicting survival from PTBD insertion. This single-centre retrospective study included 175 consecutive patients undergoing PTBD for extrahepatic CCA (perihilar and distal). Prognostic factors affecting survival of patients with CCA treated with PTBD were analysed. A multivariate analysis showed that mass forming tumor with mass larger than 5 cm and presence of metastasis at the time of PTBD served as a negative prognostic factor (p = 0.002), better survival was associated with lower preprocedural bilirubin and lower CRP (p = 0.003). Multivariate analysis identified two significant risk factors for 3-month mortality: mass-forming tumors and bilirubin levels exceeding 185 μmol/L. A simple scoring system was developed to predict 3-month mortality after PTBD in patients with advanced CCA, demonstrating 86.3% negative predictive value and 43.2% positive predictive value.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010249
003      
CZ-PrNML
005      
20250605115703.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-025-86443-8 $2 doi
035    __
$a (PubMed)39824949
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Rohan, Tomáš $u Department of Radiology and Nuclear Medicine, University Hospital Brno, Brno, 625 00, Czechia $u Medical Faculty, Masaryk University, Brno, 625 00, Czechia $7 xx0237558
245    10
$a Prognostic factors for survival in patients with advanced cholangiocarcinoma treated with percutaneous transhepatic drainage / $c T. Rohan, B. Cechova, P. Matkulcik, M. Straka, J. Zavadil, M. Eid, M. Uher, M. Dostal, T. Andrasina
520    9_
$a Biliary drainage is then one of the necessary procedures to help patients suffering from icterus to reduce serum bilirubin levels and relieve symptoms. The aim of this study was identifying risk factors for survival in patients with cholangiocarcinoma (CCA) treated with percutaneous transhepatic biliary drainage (PTBD) and to develop a simple scoring system predicting survival from PTBD insertion. This single-centre retrospective study included 175 consecutive patients undergoing PTBD for extrahepatic CCA (perihilar and distal). Prognostic factors affecting survival of patients with CCA treated with PTBD were analysed. A multivariate analysis showed that mass forming tumor with mass larger than 5 cm and presence of metastasis at the time of PTBD served as a negative prognostic factor (p = 0.002), better survival was associated with lower preprocedural bilirubin and lower CRP (p = 0.003). Multivariate analysis identified two significant risk factors for 3-month mortality: mass-forming tumors and bilirubin levels exceeding 185 μmol/L. A simple scoring system was developed to predict 3-month mortality after PTBD in patients with advanced CCA, demonstrating 86.3% negative predictive value and 43.2% positive predictive value.
650    _2
$a lidé $7 D006801
650    12
$a cholangiokarcinom $x mortalita $x terapie $x patologie $7 D018281
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a drenáž $x metody $7 D004322
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    12
$a nádory žlučových cest $x mortalita $x terapie $x patologie $7 D001650
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a bilirubin $x krev $7 D001663
650    _2
$a rizikové faktory $7 D012307
650    _2
$a dospělí $7 D000328
650    _2
$a senioři nad 80 let $7 D000369
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Čechová, Barbora $u Department of Radiology and Nuclear Medicine, University Hospital Brno, Brno, 625 00, Czechia $u Medical Faculty, Masaryk University, Brno, 625 00, Czechia $7 xx0308724
700    1_
$a Matkulcik, Peter $u Department of Radiology and Nuclear Medicine, University Hospital Brno, Brno, 625 00, Czechia $u Medical Faculty, Masaryk University, Brno, 625 00, Czechia
700    1_
$a Straka, Matej $u Medical Faculty, Masaryk University, Brno, 625 00, Czechia $u Masaryk Memorial Cancer Institute, Brno, 60200, Czechia, Czechia
700    1_
$a Zavadil, Jan $u Medical Faculty, Masaryk University, Brno, 625 00, Czechia $u University Hospital Ostrava, Ostrava, 708 00, Czechia
700    1_
$a Eid, Michal $u Medical Faculty, Masaryk University, Brno, 625 00, Czechia $u Department of Hematology, Oncology and Internal Medicine, University Hospital Brno, 625 00, Brno, Czechia
700    1_
$a Uher, Michal $u Masaryk Memorial Cancer Institute, Brno, 60200, Czechia, Czechia
700    1_
$a Dostal, Marek $u Department of Radiology and Nuclear Medicine, University Hospital Brno, Brno, 625 00, Czechia $u Medical Faculty, Masaryk University, Brno, 625 00, Czechia
700    1_
$a Andrasina, Tomas $u Department of Radiology and Nuclear Medicine, University Hospital Brno, Brno, 625 00, Czechia. andrasina.tomas@fnbrno.cz $u Medical Faculty, Masaryk University, Brno, 625 00, Czechia. andrasina.tomas@fnbrno.cz $u Department of Radiology and Nuclear Medicine, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, 625 00, Czech Republic. andrasina.tomas@fnbrno.cz
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 15, č. 1 (2025), s. 2172
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39824949 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250605115656 $b ABA008
999    __
$a ok $b bmc $g 2311551 $s 1247330
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 15 $c 1 $d 2172 $e 20250116 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
GRA    __
$a NU21-08-00561 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a NU21-08-00561 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a NU21-08-00561 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a NU21-08-00561 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a MUNI/A/1611/2023 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a MUNI/A/1611/2023 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a MUNI/A/1611/2023 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a MUNI/A/1558/2023 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a MUNI/A/1611/2023 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a MUNI/A/1611/2023 $p Ministerstvo Školství, Mládeže a Tělovýchovy
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Archiving options